Life Sciences AISeries DWorkflowℹFormation Bio
Drug development can advance faster when clinical assets, operational workflows, and accumulated evidence are coordinated through software rather than fragmented manual processes.
Company snapshot
- Stage
- Series D
- Funding
- Series D · $372M · Jun 26, 2024
- Status
- published
- Updated
- Nov 4, 2026
- Views
- Category
- Life Sciences AI
- Website
- formation.bio
What they're building
Drug development can advance faster when clinical assets, operational workflows, and accumulated evidence are coordinated through software rather than fragmented manual processes. Formation Bio acquires clinical-stage medicines and develops them using an AI-native platform, combining drug selection, trial operations, and reusable data infrastructure.
Founders
Benjamine Liu
Co-founder
Linhao Zhang
Co-founder
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Agentic loops, Batch document processing
- Potential advantages
- Workflow lock-in
- Estimated model demand
- High intensity
NYC footprint
- NYC office
- 16 East 34th Street, New York, NY 10016
Funding
Latest funding: Series D · $372M · Jun 26, 2024. Lead investor: Andreessen Horowitz.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Formerly TrialSpark. Current primary about page verifies both founders; Benjamine Liu also uses Ben Liu. The October 28, 2026 $600M Drug Development Accelerator Fund comprises commitments to a separate drug-asset investment fund and is not a new corporate equity round. Corporate stage remains the latest verified $372M Series D. Current official Greenhouse office metadata verifies 16 East 34th Street beyond the privacy notice. Copy is synthesized from cited first-party messaging; no independent performance validation is implied.
- https://www.formation.bio/ ↗
- https://www.formation.bio/about-us ↗
- https://www.formation.bio/careers ↗
- https://boards-api.greenhouse.io/v1/boards/formationbio/offices ↗
- https://www.prnewswire.com/news-releases/formation-bio-secures-372mm-series-d-funding-to-grow-drug-pipeline-and-continue-expanding-ai-driven-drug-development-platform-302182347.html ↗
- https://www.formation.bio/press/formation-bio-announces-usd600-million-debut-fund-to-expand-drug-development-capacity ↗
Manhattan · verified headquarters
16 East 34th Street, New York, NY 10016. Current first-party recruiting office endpoint lists office ID 22910 at this exact street, independently matching the company’s current careers description of its NYC headquarters. This is not a privacy-only pin. The privacy PDF lists Floor 10 but is last updated January 20, 2021; the old floor detail is not asserted as a current floor. No precise neighborhood inferred.
Formation Bio current official Greenhouse office metadata ↗Source checked 2026-11-04
Notes
Formation Bio is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹ161viewsRecent Activity
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.
Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.
Life Sciences AIInfraℹRecent Activity
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Life Sciences AIWorkflowℹRecent Activity